Soft Mist Inhaler Patents: Who Leads, Where the Gaps Are 2026
- Filings peaked in 2021 at 377 and fell to 140 by 2024, a -63% swing over that span — the sharpest contraction in the trend rather than a gradual slowdown.
- The leader holds 176 records, and the top 10 assignees together hold 30.3% of all 3,400 records, leaving a long tail of single- and few-filing entrants behind the leaders.
- A61M device claims (devices for body fluids) sit under A61K formulation claims at 27.6% versus 70.5% of records, showing the hardware side is comparatively less contested than the drug-formulation side.
Filing growth compares 2021 (377 records) with 2024 (140) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 3,400 records in scope (CR5), not by the ranked leaders only.
What the filing record shows
Soft mist inhalers and nebulizers sit at the intersection of drug formulation and delivery hardware, and the patent record reflects that split. Medicinal preparation claims (A61K) cover 70.5% of the 3,400 records in scope, far outweighing device-specific claims under A61M at 27.6%. That imbalance means most of the documented activity is about what is being delivered — a formulation, a molecule, a therapeutic use — rather than how the mist or aerosol itself is generated and metered.
Filing activity rose through the second half of the 2010s, peaked in 2021, and has come down since — publication lag means the last one to two years understate real filing activity, so the recent-year numbers should be read as a floor, not a ceiling. Coverage runs from 2015 through the 2026-07-31 cut-off across US, EPO, WIPO, Australian, Canadian and Israeli filings.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 3,400-record dataset: how filing activity has moved year over year, and which IPC subclasses carry the claim density.
A sharp pullback from the 2021 peak
Annual filings ran from 244 in 2017 to a peak of 377 in 2021, then declined to 140 by 2024 — a -63% contraction over that three-year window. Figures for 2025 and 2026 are still incomplete due to the roughly 18-month gap between filing and publication, so they should not be read as continued decline.
Formulation claims dominate the classification mix
A61K (medicinal preparations) appears on 70.5% of the 3,400 records, well ahead of A61P therapeutic-activity claims at 35.7% and A61M device claims at 27.6%. Smaller shares in C07K peptides (9.0%), C12N microorganisms (8.4%), B05B spraying and atomising (6.9%), C07C compounds (6.1%) and C07D heterocyclics (5.0%) mark the narrower technical branches. Because a single record can carry several IPC codes, these shares sum to more than 100% of the record total.
Shares are the percentage of the 3,400 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Soft Mist Inhalers and Nebulizers with Eureka
This page is one run against one query. Ask Eureka your own question about soft mist inhalers and nebulizers and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art and a representative recent filing
Use of a heparin composition in the treatment of viral lung diseases by soft mist inhaler or vibration mesh nebulizer
Filed by Istanbul Universitesi Rektorlugu and published 2024-01-11, this filing claims delivery of heparin and its derivatives — including low molecular weight heparin — for treating COVID-19 and other viral or chronic lung diseases, administered specifically via soft mist inhaler or vibrating mesh technology nebulizer through the inhalation route, using either passive or active vibrating mesh nebulizers.Abstract condensed from the original filing.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5522385A | Dynamic particle size control for aerosolized drug delivery | 512 |
| 2 | US7845359B2 | Artificial smoke cigarette | 496 |
| 3 | US6601776B1 | Liquid atomization methods and devices | 480 |
| 4 | US5544646A | Systems for the intrapulmonary delivery of aerosolized aqueous formulations | 425 |
| 5 | US8127772B2 | Nebulizer method | 392 |
| 6 | US5509404A | Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values | 376 |
| 7 | US5709202A | Intrapulmonary delivery of aerosolized formulations | 376 |
| 8 | US4268460A | Nebulizer | 356 |
| 9 | US5511726A | Nebulizer device | 349 |
| 10 | US20090291062A1 | Protein formulations and methods of making same | 346 |
Citation counts reflect influence within the searched corpus and skew toward older filings; they are not a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns worth acting on before drafting claims in this space.
The top of the field is thin relative to the tail
The top 5 assignees hold 618 records combined, 18.2% of all 3,400 records in scope, and the top 10 add up to 30.3%. That leaves the majority of filings spread across a long tail of smaller and single-filing entrants, so freedom-to-operate work has to look well past the obvious leaders.
The 2021 peak has not held
Filings ran from 244 in 2017 up to a peak of 377 in 2021, then down to 140 by 2024 — a -63% contraction over that span. Several individual leaders show flat or zero activity in the latest tracked year, consistent with a broader pullback rather than one company stepping back.
Formulation claims outweigh device claims by a wide margin
A61K medicinal-preparation claims sit on 70.5% of the 3,400 records against A61M device claims at 27.6% — device geometry, mesh actuation and breath-triggering mechanics carry comparatively less claim density than the drugs and formulations being delivered through them.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to soft mist inhalers and nebulizers, with the prior art for and against each one.
Who holds ground and where the gate sits
The leader holds 176 records; by fifth place that figure is already down to 91, and by tenth place to 76 — a fast drop-off rather than a plateau.
One clear leader, then a steep drop
The top-ranked assignee holds 176 records against 91 for fifth place and 76 for tenth — the gap between first and fifth is proportionally larger than the gap from fifth to tenth, suggesting one dominant filer rather than a tight cluster at the top.
Several leaders show no recent activity
Multiple assignees that rank among the leaders show zero filings in the latest tracked year, with year-over-year drops of -100% for some. That is consistent with the broader post-2021 pullback rather than isolated withdrawal by any single company.
Collaboration is limited and concentrated
Only 10 co-assignee pairs appear in the dataset, and the strongest of them link a small number of corporate and individual co-filers repeatedly rather than showing broad cross-company collaboration.
| Assignee | Recent year | YoY |
|---|---|---|
| Cybin Ireland Limited | 1 | -75% |
| NeOnc Technologies Inc | 0 | — |
| Insmed Inc | 0 | -100% |
| Arrowhead Pharmaceuticals Inc | 0 | -100% |
| Vectura Delivery Devices Ltd | 0 | -100% |
| Vectura GmbH | 0 | — |
| Spexis AG | 0 | — |
| Pneuma Respiratory Inc | 0 | -100% |
Where to take this next
The dataset points to specific next steps depending on whether you are clearing a filing or scoping a design-around.
Map freedom-to-operate against the long tail
With only 30.3% of records held by the top 10 assignees, a freedom-to-operate search needs to go well beyond the named leaders into the long tail of smaller filers.
Run a freedom-to-operate search in EurekaWatch the device-side white space
A61M device claims trail A61K formulation claims by a wide margin, which is where new mechanical claims are more likely to clear prior art.
Explore device-class white space in EurekaTrack the post-2021 pullback by assignee
Several leaders show flat or zero recent-year filings; confirming whether that reflects strategy shifts or publication lag needs assignee-level monitoring.
Set up assignee monitoring in EurekaCommon questions on this landscape
This dataset covers 3,400 published patent records filed or published between 2015 and the 2026-07-31 cut-off, searched against soft mist inhaler and nebulizer terms combined with mesh nebulizer, droplet size, delivery efficiency and related technical terms. That figure counts records, not distinct inventions, since some inventions generate multiple related filings across jurisdictions. Filing activity peaked in 2021 at 377 records and has since declined to 140 by 2024, the last year that can be treated as complete given publication lag.
The dataset ranks 100 assignees by patent family count, with the leader holding 176 records against 91 for the fifth-ranked assignee and 76 for tenth. The top 5 combined hold 18.2% of all 3,400 records in scope, and the top 10 hold 30.3%, which means the majority of filing activity sits outside the ranked leaders in a long tail of smaller filers. This concentration pattern matters for freedom-to-operate work, since clearing only the named leaders would miss most of the field.
Filings rose from 244 in 2017 to a peak of 377 in 2021, then fell to 140 by 2024 — a -63% decline over that three-year span. That is a real contraction, not a data artefact, but the 2025 and 2026 figures should not be read into that trend because publication typically lags filing by around 18 months, so the most recent one to two years always understate true filing activity. The complete picture through 2024 shows a pullback from a clear 2021 peak.
In this dataset, most claim density sits on the formulation side: A61K medicinal-preparation claims appear on 70.5% of the 3,400 records, well ahead of A61M device claims at 27.6%. That means the bulk of documented invention activity concerns what drug or compound is being delivered and for what therapeutic use, rather than the mechanical design of the mist-generation or nebulizing hardware itself. Device-specific mechanisms such as mesh actuation and breath-triggering show comparatively lower filing density, which is where more open claim space tends to sit.
The technology composition data shows device-class claims (A61M, B05B) trailing formulation and therapeutic claims (A61K, A61P) by a wide margin, which points to under-claimed mechanical sub-areas including mesh actuation frequency control, breath-actuation trigger mechanisms, cleaning-cycle automation and droplet-size feedback control. These are narrower technical branches rather than broad open fields, so a first claim there would need to be specific to a mechanism rather than a general device category. Confirming true openness still requires a targeted prior-art search beyond this dataset's composition figures.
Research Soft Mist Inhalers and Nebulizers in depth with Eureka
Go past this page: query the whole soft mist inhalers and nebulizers corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.